← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $616B	4,199	+105	+3%	$321B
2	2 AbbVie ABBV $507B	3,919	+130	+3%	$294B
3	3 Merck MRK $367B	3,319	-16	-0.5%	$160B
4	4 Amgen AMGN $238B	2,827	-31	-1%	$119B
5	5 Pfizer PFE $169B	2,820	+4	+0.1%	$92.5B
6	6 Bristol-Myers Squibb BMY $125B	2,277	-23	-1%	$71.6B
7	7 Gilead Sciences GILD $197B	2,034	+8	+0.4%	$117B
8	8 Novartis NVS $287B	1,405	+19	+1%	$17.2B
9	9 AstraZeneca AZN $260B	1,290	+66	+5%	$37.9B
10	10 Regeneron Pharmaceuticals REGN $82.7B	1,246	+43	+4%	$49B
11	11 GSK GSK $98.5B	897	+5	+0.6%	$16.7B
12	12 Incyte INCY $23.1B	714	+55	+8%	$16.8B
13	13 Natera NTRA $57.9B	686	+39	+6%	$20.8B
14	14 Exelixis EXEL $15.6B	621	-14	-2%	$10.4B
15	15 Halozyme HALO $13.8B	603	+52	+9%	$8.75B
16	16 DELISTED Exact Sciences EXAS	569	+10	+2%	$9.7B
17	17 Jazz Pharmaceuticals JAZZ $13.9B	503	+1	+0.2%	$8.01B
18	18 Tempus AI TEM $12.7B	440	+71	+19%	$7.47B
19	19 Lantheus LNTH $6.53B	419	-57	-12%	$3.66B
20	20 Guardant Health GH $22.1B	395	+30	+8%	$7.65B
21	21 Qiagen QGEN $9.58B	340	+21	+7%	$6.84B
22	22 Takeda Pharmaceutical TAK $62.7B	331	+14	+4%	$1.25B
23	23 Revolution Medicines RVMD $41B	323	+15	+5%	$8.96B
24	24 Recursion Pharmaceuticals RXRX $2.28B	322	-10	-3%	$1.58B
25	25 Veracyte VCYT $3.63B	298	+20	+7%	$3.08B